Lineage Cell Therapeutics Logo
US53566P1093
A2PP89
LCTX.TA

Lineage Cell Therapeutics

Previsioni

Acquista
  5
Mantieni
  0
Vendi
  0

Discussioni nella community

Non ci sono ancora discussioni su questo asset.

Avvia discussione

  • Lineage Cell Therapeutics advances preclinical pipeline and extends cash runway to Q3 2028

    Lineage reported preclinical progress in corneal disease, Type 1 diabetes and hearing-loss programs while Roche and Genentech continue optimizing surgical delivery for lead OpRegen. The OPC1 DOSED study has treated two chronic spinal-cord-injury patients with no unexpected safety issues, though it is not designed to assess efficacy. Lineage highlighted its AlloSCOPE manufacturing platform aimed at scalable allogeneic production and said existing GMP banks have been FDA-cleared and used in OpRegen trials. The company ended Q2 with $50.8 million in cash and marketable securities, extending its expected runway into Q3 2028, and remains eligible for up to $615 million in milestones plus tiered royalties from the Roche/Genentech deal. » Altro su finance.yahoo.com


  • Lineage Cell Therapeutics reports Q2 profit and extends financing through Q3 2028

    Lineage Cell Therapeutics reported a net profit of $1.5 million in the second quarter of 2026 on revenue that fell to $1.1 million. Cash and marketable securities amounted to $50.8 million as of June 30, which the company says finances operations through the third quarter of 2028. The reported gain was largely non‑cash, stemming from a revaluation of option-related liabilities, while operating activities still showed a loss of $8.9 million. Management emphasizes the “Lineage 3.0” platform strategy and points to ongoing partnerships such as OpRegen with Roche/Genentech, as well as expected pipeline updates before the end of 2026. » Altro su de.investing.com


  • Lineage Cell Therapeutics files prospectus supplement for stock offering of up to $60 million

    Lineage Cell Therapeutics has filed a prospectus supplement with the SEC for the potential sale of common stock totaling up to $60 million. The shares would be offered from time to time under an existing distribution agreement with B. Riley Securities; the supplement is part of an existing shelf registration (Form S-3). The company emphasized that the notice does not constitute an offer to sell and attached a legal opinion; it also highlighted progress in the OpRegen program with Roche/Genentech and received a buy recommendation from H.C. Wainwright with a $9.00 price target. » Altro su de.investing.com


  • Lineage Cell Therapeutics withdraws CIRM grant application and plans resubmission

    Lineage Cell Therapeutics withdrew its CLIN2 grant application to the California Institute for Regenerative Medicine after receiving feedback and plans to submit a revised application in the next CIRM cycle in January 2026. CIRM did not identify any specific substantive deficiencies, and the company will continue development activities for OPC1 unchanged. The ongoing DOSED study for OPC1 administration is proceeding as planned. Lineage also reported Q3 results with EPS of -$0.13 (below expectations) and revenue of $3.68 million (above expectations), raised $21 million through an ATM sale, and reported its stock price and market capitalization. » Altro su de.investing.com


  • Lineage reaches 52-week low at $32.78

    Lineage stock fell to a 52-week low of $32.78 and is currently trading near that level, well below its high of $66.38. Year-to-date the price is down about 41.04%, and it fell 48.21% last year. InvestingPro rates the stock as fairly valued, with analyst price targets ranging from $38 to $70. For Q3 Lineage reported record revenue of $1.37 billion but posted a loss per share and cut its full-year forecast; several banks have lowered price targets or adjusted ratings. Despite the loss, Lineage offers a dividend yield of 6.32%, providing investors with short-term income at increased risk. » Altro su de.investing.com

Nel 2003, Lineage Cell Therapeutics ha già distribuito 0,0651 € di dividendi. L'ultimo pagamento è avvenuto a dicembre 2003.

Dati finanziari

Nell'ultimo trimestre, Lineage Cell Therapeutics ha registrato ricavi pari a 1,27 Mln € e un utile netto di 3,74 Mln €

(EUR) settembre 2026
YoY
Ricavi 1,27 Mln 59,64%
Utile lordo 1,26 Mln 59,72%
Utile netto 3,74 Mln 114,72%
EBITDA 4,34 Mln 117,22%

Dati fondamentali

Metrica Valore
Capitalizzazione di mercato
177,95 Mln €
Numero di azioni
252,95 Mln
Massimo/minimo a 52 settimane
1,81 € - 0,70 €
Dividendi No
Beta
1,69
Rapporto P/E
-25,56
Rapporto PEG
-0,15
Rapporto P/B
2,91
Rapporto P/S
18,02

Profilo aziendale

Lineage Cell Therapeutics, Inc., una società di biotecnologia in fase clinica, sviluppa nuove terapie cellulari per il trattamento di malattie degenerative negli Stati Uniti e a livello internazionale. La società sviluppa OpRegen, una terapia di sostituzione delle cellule dell'epitelio pigmentato retinico, che è in sperimentazione clinica di Fase I/IIa per il trattamento della degenerazione maculare senile secca; OPC1, una terapia con cellule progenitrici degli oligodendrociti, che è in sperimentazione clinica multicentrica di Fase I/IIa per il trattamento delle lesioni acute del midollo spinale; e VAC2, un'immunoterapia allogenica contro il cancro basata su cellule dendritiche presentanti l'antigene, che è in sperimentazione clinica di Fase I per il trattamento del carcinoma polmonare non a piccole cellule. Offre inoltre Renevia, un prodotto per l'estetica del viso. Inoltre, la società svolge attività di ricerca e sviluppo di prodotti terapeutici per malattie retiniche, malattie neurologiche e disturbi e oncologia. Lineage Cell Therapeutics, Inc. ha una collaborazione con Orbit Biomedical, Ltd. La società era precedentemente nota come BioTime, Inc. e ha cambiato denominazione in Lineage Cell Therapeutics, Inc. nell'agosto 2019. Lineage Cell Therapeutics, Inc. è stata costituita nel 1990 e ha sede a Carlsbad, in California.

Nome
Lineage Cell Therapeutics
CEO
Brian Culley
Sede centrale Carlsbad, ca
Stati Uniti
Sito web
Settore
Beni di prima necessità
Industria
Prodotti alimentari
Quotazione in borsa
05/03/1992
Dipendenti 75

Simboli di borsa

Borsa Simbolo
Tlv
LCTX.TA
AMEX
LCTX
Frankfurt
BT3.F
Düsseldorf
BT3.DU
🍪

Parqet  usa i cookie. Scopri di più